疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 2703人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1720981, encodeId=16011e2098158, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Rheumatol：TYK2抑制剂PF-06826647治疗银屑病的疗效和安全性, objectType=article, longId=205276, objectId=378a2052e6cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=378a2052e6cd, replyNumber=0, likeNumber=63, createdTime=2021-02-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=378a2052e6cd, moduleTitle=Lancet Rheumatol：TYK2抑制剂PF-06826647治疗银屑病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=378a2052e6cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721063, encodeId=846a1e2106395, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Arthritis Rheumatol：阿那白滞素治疗痛风发作的疗效和安全性, objectType=article, longId=215836, objectId=02f2215836de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02f2215836de, replyNumber=0, likeNumber=65, createdTime=2022-05-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02f2215836de, moduleTitle=Arthritis Rheumatol：阿那白滞素治疗痛风发作的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02f2215836de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721046, encodeId=c8381e210468f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, objectType=article, longId=213367, objectId=676e21336e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676e21336e25, replyNumber=0, likeNumber=81, createdTime=2022-02-28, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676e21336e25, moduleTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676e21336e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720983, encodeId=65a51e209833a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Prostate Cancer：纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究, objectType=article, longId=205674, objectId=19872056e42f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19872056e42f, replyNumber=0, likeNumber=93, createdTime=2021-07-28, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19872056e42f, moduleTitle=Prostate Cancer：纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19872056e42f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720999, encodeId=aa891e20999c3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur Urol：转移性肾细胞癌患者接受Atezolizumab或Sunitinib单药治疗疾病进展后使用Atezolizumab加Bevacizumab的疗效和安全性 , objectType=article, longId=208763, objectId=25ad208e63d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ad208e63d1, replyNumber=0, likeNumber=53, createdTime=2021-03-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ad208e63d1, moduleTitle=Eur Urol：转移性肾细胞癌患者接受Atezolizumab或Sunitinib单药治疗疾病进展后使用Atezolizumab加Bevacizumab的疗效和安全性 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ad208e63d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721052, encodeId=30fd1e2105248, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, objectType=article, longId=214070, objectId=468d2140e0fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468d2140e0fd, replyNumber=0, likeNumber=77, createdTime=2021-12-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468d2140e0fd, moduleTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=468d2140e0fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721136, encodeId=0b2e1e2113658, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, objectType=article, longId=221380, objectId=bb87221380d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb87221380d6, replyNumber=0, likeNumber=68, createdTime=2022-10-11, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb87221380d6, moduleTitle=Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb87221380d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721058, encodeId=83c71e2105812, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Diabetes Obes Metab：口服胰岛素ORMD-0801治疗2型糖尿病的疗效和安全性, objectType=article, longId=215208, objectId=74d4215208a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74d4215208a5, replyNumber=0, likeNumber=68, createdTime=2022-05-08, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74d4215208a5, moduleTitle=Diabetes Obes Metab：口服胰岛素ORMD-0801治疗2型糖尿病的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74d4215208a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721029, encodeId=14411e21029f7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, objectType=article, longId=212429, objectId=7a5c212429e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5c212429e5, replyNumber=0, likeNumber=79, createdTime=2022-05-03, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5c212429e5, moduleTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5c212429e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720987, encodeId=0c5d1e2098702, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：新型选择性ER降解剂Elacestrant治疗ER+HER2-晚期乳腺癌的疗效和安全性, objectType=article, longId=206593, objectId=f30c2065934e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f30c2065934e, replyNumber=0, likeNumber=76, createdTime=2021-04-17, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f30c2065934e, moduleTitle=J Clin Oncol：新型选择性ER降解剂Elacestrant治疗ER+HER2-晚期乳腺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f30c2065934e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721049, encodeId=518f1e2104937, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Oncol：帕妥珠单抗+曲妥珠单抗+紫杉类一线治疗HER2阳性局部复发或转移性乳腺癌的疗效和安全性：PERUSE研究的最终分析, objectType=article, longId=214034, objectId=f1b7214034fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1b7214034fe, replyNumber=0, likeNumber=78, createdTime=2021-12-23, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1b7214034fe, moduleTitle=Ann Oncol：帕妥珠单抗+曲妥珠单抗+紫杉类一线治疗HER2阳性局部复发或转移性乳腺癌的疗效和安全性：PERUSE研究的最终分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1b7214034fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721072, encodeId=7a4c1e210721b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JNCCN：卡培他滨/替莫唑胺(CAPTEM)治疗神经内分泌肿瘤的疗效和安全性, objectType=article, longId=216808, objectId=6a23216808c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a23216808c1, replyNumber=0, likeNumber=86, createdTime=2022-01-13, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a23216808c1, moduleTitle=JNCCN：卡培他滨/替莫唑胺(CAPTEM)治疗神经内分泌肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a23216808c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720991, encodeId=912a1e2099150, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Circulation：房颤患者采用依多沙班治疗的疗效和安全性的性别差异, objectType=article, longId=207333, objectId=603520e33341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=603520e33341, replyNumber=0, likeNumber=70, createdTime=2022-01-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=603520e33341, moduleTitle=Circulation：房颤患者采用依多沙班治疗的疗效和安全性的性别差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=603520e33341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721004, encodeId=a92d1e2100437, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Rheum Dis：他那珠单抗治疗髋关节或膝关节骨性关节炎的疗效和安全性, objectType=article, longId=210115, objectId=3bd92101152f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bd92101152f, replyNumber=0, likeNumber=70, createdTime=2021-07-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bd92101152f, moduleTitle=Ann Rheum Dis：他那珠单抗治疗髋关节或膝关节骨性关节炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bd92101152f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721001, encodeId=f1b01e21001fd, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur Heart J：低剂量秋水仙碱对冠心病患者的疗效和安全性分析, objectType=article, longId=209101, objectId=7e00209101cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e00209101cf, replyNumber=0, likeNumber=79, createdTime=2021-08-04, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e00209101cf, moduleTitle=Eur Heart J：低剂量秋水仙碱对冠心病患者的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e00209101cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721019, encodeId=d63d1e21019c2, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, objectType=article, longId=211491, objectId=32e221149157, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32e221149157, replyNumber=0, likeNumber=65, createdTime=2021-06-27, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32e221149157, moduleTitle=Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32e221149157)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721100, encodeId=d1c11e21100f0, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Cancer Commun：抗HER2抗体RC48治疗HER2过表达晚期胃癌(GC)或胃食管交界处癌(GEJA)的疗效和安全性：单臂II期研究, objectType=article, longId=219112, objectId=3ad22191126f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ad22191126f, replyNumber=0, likeNumber=90, createdTime=2022-08-26, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ad22191126f, moduleTitle=Cancer Commun：抗HER2抗体RC48治疗HER2过表达晚期胃癌(GC)或胃食管交界处癌(GEJA)的疗效和安全性：单臂II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ad22191126f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721050, encodeId=30471e21050f3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Nat Med：Efruxifermin治疗非酒精性脂肪性肝炎的疗效和安全性分析, objectType=article, longId=214042, objectId=005e214042e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=005e214042e3, replyNumber=0, likeNumber=63, createdTime=2021-12-30, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=005e214042e3, moduleTitle=Nat Med：Efruxifermin治疗非酒精性脂肪性肝炎的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=005e214042e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721048, encodeId=34431e2104867, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, objectType=article, longId=213612, objectId=25b221361280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b221361280, replyNumber=0, likeNumber=59, createdTime=2021-07-20, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b221361280, moduleTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b221361280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721022, encodeId=37ac1e2102241, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur J Cancer:来那替尼（Neratinib）延伸辅助治疗在HER2/HR共阳性早期乳腺癌患者的疗效和安全性分析：来自德国ExteNET研究的亚组分析结果, objectType=article, longId=211719, objectId=a8bf211e192d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8bf211e192d, replyNumber=0, likeNumber=99, createdTime=2022-03-04, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8bf211e192d, moduleTitle=Eur J Cancer:来那替尼（Neratinib）延伸辅助治疗在HER2/HR共阳性早期乳腺癌患者的疗效和安全性分析：来自德国ExteNET研究的亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8bf211e192d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet Rheumatol：TYK2抑制剂PF-06826647治疗银屑病的疗效和安全性

2021-02-16

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Arthritis Rheumatol：阿那白滞素治疗痛风发作的疗效和安全性

2022-05-16

智慧医人 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究

2022-02-28

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Prostate Cancer：纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究

2021-07-28

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur Urol：转移性肾细胞癌患者接受Atezolizumab或Sunitinib单药治疗疾病进展后使用Atezolizumab加Bevacizumab的疗效和安全性

2021-03-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究

2021-12-01

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Oncologist: Sorafenib（索拉非尼）联合Capecitabine（卡培他滨）治疗既往治疗过的转移性结直肠癌患者的疗效和安全性

2022-10-11

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Diabetes Obes Metab：口服胰岛素ORMD-0801治疗2型糖尿病的疗效和安全性

2022-05-08

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。

2022-05-03

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Clin Oncol：新型选择性ER降解剂Elacestrant治疗ER+HER2-晚期乳腺癌的疗效和安全性

2021-04-17

智慧医人 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Oncol：帕妥珠单抗+曲妥珠单抗+紫杉类一线治疗HER2阳性局部复发或转移性乳腺癌的疗效和安全性：PERUSE研究的最终分析

2021-12-23

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JNCCN：卡培他滨/替莫唑胺(CAPTEM)治疗神经内分泌肿瘤的疗效和安全性

2022-01-13

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Circulation：房颤患者采用依多沙班治疗的疗效和安全性的性别差异

2022-01-14

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Rheum Dis：他那珠单抗治疗髋关节或膝关节骨性关节炎的疗效和安全性

2021-07-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur Heart J：低剂量秋水仙碱对冠心病患者的疗效和安全性分析

2021-08-04

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Liver Cancer：多激酶抑制剂二线疗法用于晚期HCC的疗效和安全性

2021-06-27

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Cancer Commun：抗HER2抗体RC48治疗HER2过表达晚期胃癌(GC)或胃食管交界处癌(GEJA)的疗效和安全性：单臂II期研究

2022-08-26

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Nat Med：Efruxifermin治疗非酒精性脂肪性肝炎的疗效和安全性分析

2021-12-30

智慧医人 (审核中...)

前往app查看评论内容

#疗效和安全性#

Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验

2021-07-20

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur J Cancer:来那替尼（Neratinib）延伸辅助治疗在HER2/HR共阳性早期乳腺癌患者的疗效和安全性分析：来自德国ExteNET研究的亚组分析结果

2022-03-04

科室
- - 订阅+
  - 更多科室
工具
服务